High-dose inactivated influenza vaccinations from community pharmacists during 2012-2013 flu season were more effective than standard-dose inactivated flu shots in patients 65 years and older, and helped in the prevention of influenza-associated hospitalizations, according to a comparative effectiveness study published in The Lancet Infectious Diseases.
FDA has approved two new HIV-1 cocktail drugs: elvitegravir (Vitekta, Gilead), an integrase inhibitor and cobicistat (Tybost, Gilead), a protease-inhibitor booster.
Researchers from the Centers for Disease Control and Prevention (CDC) and FDA undertook a study to determine the most commonly implicated active ingredients responsible for childhood poisonings that required emergency hospitalization in the hope of identifying prevention and intervention strategies. Buprenorphine and clonidine were the most common of 12 active ingredients that were found in 45.0% of these hospitalizations.
NOH is a rare, chronic, and debilitating drop in blood pressure upon standing. It is associated with Parkinson's disease, multiple system atrophy, and pure autonomic failure.
FDA has approved empagliflozin (Jardiance, Boehringer Ingelheim Pharmceuticals) as another option for adult patients with type 2 diabetes.
FDA approved eslicarbazepine acetate on November 8, 2013 as an adjunctive treatment of partial-onset seizures in adults.
Benzodiazepines and opioid medications have dangerous synergistic effects. The use of both has climbed in the last decade, and so has co-prescription.
A penicillin "allergy" label adversely affects the quantity and quality of healthcare in hospitalized patients, a new study reports.
Teva Pharmaceutical Industries launched loxapine inhalation powder, 10 mg (Adasuve) March 3, for the acute treatment of agitation associated with schizophrenia or bipolar 1 disorder in adults.
Pharmacy groups, representing more than 100,000 pharmacists in different pharmacy practice settings, have written to CMS Administrator Marilyn B. Tavenner to express their support for the expansion of medication therapy management (MTM) services to Medicare Part D beneficiaries in the CMS proposal released in early January.